Shares of ProMetic Life Sciences Inc. (TSE:PLI – Get Rating) crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of C$0.00 and traded as high as C$13.72. ProMetic Life Sciences shares last traded at C$13.60, with a volume of 921 shares traded.
ProMetic Life Sciences Price Performance
The company has a current ratio of 4.06, a quick ratio of 3.66 and a debt-to-equity ratio of 37.47. The stock has a market cap of C$317.06 million and a price-to-earnings ratio of -0.22.
ProMetic Life Sciences Company Profile
Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals.
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.